Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al.

dc.contributor.authorOnal, Cem
dc.contributor.authorOymak, Ezgi
dc.contributor.authorGuler, Ozan Cem
dc.contributor.orcID0000-0002-2742-9021en_US
dc.contributor.pubmedID34115258en_US
dc.contributor.researcherIDD-5195-2014en_US
dc.date.accessioned2022-09-07T12:23:58Z
dc.date.available2022-09-07T12:23:58Z
dc.date.issued2021
dc.identifier.issn1357-0560en_US
dc.identifier.issue7en_US
dc.identifier.scopus2-s2.0-85107585717en_US
dc.identifier.urihttp://hdl.handle.net/11727/7577
dc.identifier.volume38en_US
dc.identifier.wos000660549900001en_US
dc.language.isoengen_US
dc.relation.isversionof10.1007/s12032-021-01528-4en_US
dc.relation.journalMEDICAL ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleUpfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance: in regard to Triggiani et al.en_US
dc.typeLetteren_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: